HbSC disease: A time for progress

Caterina Minniti—Consultancy for Global Blood Therapeutics, Sangamo, SanguineBio, Forma, Agios, NovoNordisk, Emmaus, Novartis. End point adjudicator: Bluebird Bio; Safety Committee: CSL Behring. Carlo Brugnara—Consulting agreement with Pfizer Inc on sickle cell disease. Martin H. Steinberg—Consultant, Vertex, Astellas, Fulcrum. Not applicable.